Spotlight – still plenty of hopefuls in lung fibrosis
Roche’s zinpentraxin alfa is out of the running, but Bristol, Blade, Pliant and others have contenders in the mid-stage idiopathic pulmonary fibrosis pipeline.
Astra tentatively takes Tigit pivotal
Bispecifics targeting Tigit and CTLA4 head into phase 3 development, as the developer follows Bristol out of IL-12.
Biotech’s key upcoming clinical results
Moderna, Biomarin and Daiichi Sankyo will begin 2023 with important data reveals.
Pressure piles up on pamrevlumab
After the latest roxadustat clanger a phase 3 interim analysis in pancreatic cancer becomes even more important for Fibrogen.
The quest for efficacy in pancreatic cancer
Late-stage therapies from Fibrogen, Tyme and Novartis need to avoid the same pitfalls as Erytech and Rafael.
